37.88
-2.13(-5.32%)
Currency In USD
| Previous Close | 40.01 |
| Open | 39.44 |
| Day High | 40.58 |
| Day Low | 37.28 |
| 52-Week High | 58.4 |
| 52-Week Low | 17.86 |
| Volume | 1.76M |
| Average Volume | 1.12M |
| Market Cap | 3.02B |
| PE | -10.1 |
| EPS | -3.75 |
| Moving Average 50 Days | 41.55 |
| Moving Average 200 Days | 34.47 |
| Change | -2.13 |
If you invested $1000 in Akero Therapeutics, Inc. (AKRO) since IPO date, it would be worth $2,067.69 as of May 15, 2025 at a share price of $37.88. Whereas If you bought $1000 worth of Akero Therapeutics, Inc. (AKRO) shares 5 years ago, it would be worth $1,647.67 as of May 15, 2025 at a share price of $37.88.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
GlobeNewswire Inc.
May 10, 2025 2:00 PM GMT
Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response Data contribute to growing body of support around the anti-fibrotic activity of EFX in patients with pre-cirrhotic MASH SOUT
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
GlobeNewswire Inc.
May 09, 2025 11:11 AM GMT
Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at EASL Congress 2025 SOUTH SAN FRANCISCO, Calif., May
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
GlobeNewswire Inc.
May 09, 2025 10:15 AM GMT
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, p